Overview

A Phase II Study of AK117/AK112 in Combination With Chemotherpy for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer

Status:
Not yet recruiting

Trial end date:
2023-10-30

Target enrollment:

Participant gender:

Summary

This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK117/AK112 administered with chemotherpy in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).

Phase:

Phase 2

Details

Lead Sponsor:

Akeso

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel